Known targets — ChEMBL curated mechanism
PDE10APDE1APDE1BPDE1CPDE2APDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE6APDE6BPDE6CPDE6DPDE6GPDE6HPDE7APDE7BPDE8APDE8BPDE9ASLC29A1
The experimentally established mechanism targets of Dipyridamole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 known ✓ | Q99808 | 19/20 | 0.83 |
| ▸ | PDE2A known ✓ | O00408 | 1/20 | 0.83 |
| ▸ | PDE6D known ✓ | O43924 | 1/20 | 0.83 |
| ▸ | PDE8A known ✓ | O60658 | 1/20 | 0.83 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.83 |
| ▸ | PDE6A known ✓ | P16499 | 1/20 | 0.83 |
| ▸ | PDE6G known ✓ | P18545 | 1/20 | 0.83 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.83 |
| ▸ | PDE6B known ✓ | P35913 | 1/20 | 0.83 |
| ▸ | PDE6C known ✓ | P51160 | 1/20 | 0.83 |
| ▸ | PDE1A known ✓ | P54750 | 1/20 | 0.83 |
| ▸ | PDE1B known ✓ | Q01064 | 1/20 | 0.83 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.83 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.83 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.83 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.83 |
| ▸ | PDE7A known ✓ | Q13946 | 1/20 | 0.83 |
| ▸ | PDE6H known ✓ | Q13956 | 1/20 | 0.83 |
| ▸ | PDE1C known ✓ | Q14123 | 1/20 | 0.83 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipyridamole SCHEMBL28728392 | 0.92 | SLC29A1 (0.79) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL17044166 | 0.91 | SLC29A1 (0.94) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL3980595 | 0.91 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL29381078 | 0.91 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL16119 | 0.91 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| SCHEMBL30416820 | 0.91 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL611283 | 0.90 | SLC29A1 (0.91) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL7362290 | 0.90 | SLC29A1 (0.97) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL9743915 | 0.90 | SLC29A1 (0.97) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL28672572 | 0.90 | SLC29A1 (0.97) | SLC29A1ADORA3KDM4EMEN1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2279742-A2 | Combinations for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20090005358-A1 | Compositions and methods for treating medical conditions | LG CHEM, LTD. (KR) | 2009-01-01 | — | — | US | claimed |
| WO-2009002507-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-12-31 | — | — | WO | claimed |
| EP-1999626-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH | CombinatoRx, Incorporated (US) | 2008-12-10 | — | — | EP | claimed |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | COMBINATORX, INCORPORATED | 2008-01-31 | — | — | US | claimed |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | COMBINATORX, INC. | 2008-01-03 | — | — | US | claimed |
| EP-1680121-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2007146012-A1 | TREATMENT OF PERIODONTAL DISEASE ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN LEVELS | COMBINATORX, INCORPORATED (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2007089617-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH | COMBINATORX, INCORPORATED (US) | 2007-08-09 | — | — | WO | claimed |
| JP-2007508391-A | — | — | 2007-04-05 | — | — | JP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| EP-1448205-A4 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1680121-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | claimed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005358-A1 | Compositions and methods for treating medical conditions | ITCH, TSLP, P2RX5 | SLC29A1 2433/4885PDE2A 658/4885PDE6D 892/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | SLC29A1 1552/4885PDE2A 1857/4885PDE6D 3011/4885 |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | TYMP, TTR, TPMT | SLC29A1 908/4885PDE2A 880/4885PDE6D 1132/4885 |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, TPMT | SLC29A1 1069/4885PDE2A 1320/4885PDE6D 2710/4885 |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | IFNG, IL6, IL36G | SLC29A1 871/4885PDE2A 182/4885PDE6D 283/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | SLC29A1 1552/4885PDE2A 1857/4885PDE6D 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.